Potential pediatric intensive care unit demand/capacity mismatch due to novel pH1N1 in Canada

David Stiff1, Anand Kumar, Niranjan Kissoon

  • 1Risk Analytica Research, Toronto, ON, Canada.

Insights

Pandemic models predict significant pediatric intensive care unit (PICU) shortages for ventilation and critical care, even with vaccination. Reducing the attack rate through measures like vaccination or social distancing is crucial for maintaining pediatric care capacity.

Area of Science:

  • Epidemiology
  • Public Health
  • Critical Care Medicine

Background:

  • The emergence of the swine-origin pH1N1 virus raised concerns about pediatric critical care capacity.
  • Pandemic preparedness requires understanding potential shortfalls in pediatric intensive care units (PICUs).

Purpose of the Study:

  • To investigate potential pediatric intensive care unit shortfalls using pandemic models.
  • To assess the impact of vaccination on pediatric critical care demand during a pandemic.

Main Methods:

  • Simulation modeling was used to predict pediatric intensive care demand based on pH1N1 pandemic predictions.
  • Canadian data from the first pH1N1 wave informed models for potential second-wave scenarios.

Main Results:

  • Significant PICU shortages are expected in Canada, even with low attack rates (15%).
  • Vaccination strategies targeting 50% of the population reduced demand but did not eliminate potential shortages.
  • Ontario and British Columbia may face the most significant supply-demand differences.

Conclusions:

  • Reducing the attack rate in children is critical for ensuring adequate PICU capacity.
  • Vaccination and non-pharmaceutical interventions like social distancing are vital for pandemic preparedness in pediatric critical care.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...